Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Lasers Could Destroy Blood-borne Diseases

By Drug Discovery Trends Editor | November 1, 2007

Physicists in Arizona State University have designed a laser technique which can destroy viruses and bacteria such as AIDS without damaging human cells and may also help reduce the spread of hospital infections such as MRSA. The research, published  in the Institute of Physics’ Journal of Physics: Condensed Matter, discusses how pulses from an infrared laser can be fine-tuned to discriminate between problem microorganisms and human cells.

Current laser treatments such as UV are indiscriminate and can cause ageing of the skin, damage to the DNA or, at worst, skin cancer, and are far from 100 per cent effective. Femtosecond laser pulses, through a process called Impulsive Stimulated Raman Scattering (ISRS), produces lethal vibrations in the protein coat of microorganisms, thereby destroying them.  The effect of the vibrations is similar to that of high-pitched noise shattering glass.

The physicists in Arizona have undertaken experiments to show that the coherent vibrations excited by infrared lasers with carefully selected wavelengths and pulse widths do no damage to human cells, most likely because of the different structural compositions in the protein coats of human cells vis a vis bacteria and viruses.

Release date: October 31, 2007

Source: Institute of Physics


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE